COMP <GO>
PTCT vs MRK // FREE CASH FLOW YIELD
PTC Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: PTCT 9
— MRK 6
▲ FREE CASH FLOW YIELD LEADER: PTCT
LAST: $59.97 (-6.97%) • MKT CAP: $5.38B
fcf-yield
13.05%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTCT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTCT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 20.70% | +64.30 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.5x | 15.3x | -8.80 | PTCT | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 13.05% | 3.42% | +9.63 | PTCT | /fcf-yield <GO> |
| Operating Margin | 50.10% | 34.30% | +15.80 | PTCT | /operating-margins <GO> |
| Net Profit Margin | 39.50% | 28.10% | +11.40 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | 114.50% | 1.30% | +113.20 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.73 | 5.19 | -3.46 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | PTCT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.60% | +0.80 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.5 | 56.9 | -15.32 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.92 | +0.23 | PTCT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.6x | 18.4x | -11.80 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.38B | $361.02B | -$355.64B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTCT REV | MRK REV | PTCT GROSS % | MRK GROSS % | PTCT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.73B | $65.01B | 44.0% | 74.8% | $702.3M | $12.36B |
| FY 2024 | $806.8M | $64.17B | 44.0% | 76.3% | -$114.2M | $18.10B |
| FY 2023 | $937.8M | $60.12B | 44.0% | 44.0% | -$200.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTCT // BETA 1.15
MRK // BETA 0.92